Overview

Chairs: Dr Miles Andrews and Dr Lavinia Spain, ASM Co-Convenors

This session features five rapid presentations introducing key emerging therapies—such as cell therapy, bispecifics, and antibody-drug conjugates—alongside landmark clinical data supporting their use in solid tumours (or haematological malignancies for CAR-T).

Speakers will explain how each modality works, its stage of clinical development, and typical toxicities. The cell therapy segment will also touch on the logistics of delivering or developing these therapies in Australia.

A panel discussion with all speakers and international experts will follow, offering further insights and real-world perspectives.